Siemens Healthineers Adds Muscle To Global Antibody Testing Effort, In Talks With Vaccine Developers
The company now has US emergency use designation for its new SARS-CoV-2 test, which can run on its global installed base of 20,000 analyzers at a current capacity of 50 million tests per month.
You may also be interested in...
The test measures the relative level of antibodies, which could aid vaccine rollout.
The tests shouldn’t be used as diagnostics, but will give researchers more information about the body’s COVID-19 response.
While the main role of SARS-CoV-2 antibody testing is currently limited to determining exposure to the virus in populations, the scientific community is working hard to define the neutralizing properties of the antibodies detected, and the duration of the immune response. As a result, antibody testing could be here to stay for the long term for monitoring populations, testing vaccines and selecting patients for trials of a variety of new therapies to treat numerous conditions.